Terms: = Thyroid cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
192 results:
1. Decabromodiphenyl ether exposure reduces dabrafenib sensitivity of papillary thyroid carcinoma harboring BRAF
Wang X; Cui X; Wang Y; Wang Q; Sun F; Liu Z
Toxicology; 2024 May; 504():153807. PubMed ID: 38641160
[TBL] [Abstract] [Full Text] [Related]
2. thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study.
Kennedy OJ; Ali N; Lee R; Monaghan P; Adam S; Cooksley T; Lorigan P
Eur J Cancer; 2024 May; 202():113949. PubMed ID: 38432099
[TBL] [Abstract] [Full Text] [Related]
3. Lazertinib as a frontline treatment in patients with egfr-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.
Chul Cho B; Han JY; Hyeong Lee K; Lee YG; Kim DW; Joo Min Y; Kim SW; Kyung Cho E; Kim JH; Lee GW; Sook Lee S; Lee N; Young Wang J; Park H; Ahn MJ
Lung Cancer; 2024 Apr; 190():107509. PubMed ID: 38432025
[TBL] [Abstract] [Full Text] [Related]
4. Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib.
Fukuda N; Toda K; Suto H; Oki R; Wang X; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Endocr J; 2024 Apr; 71(4):363-371. PubMed ID: 38296547
[TBL] [Abstract] [Full Text] [Related]
5. Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve thyroid cancer with Aggressive Behavior.
Revilla G; Al Qtaish N; Caruana P; Sainz-Ramos M; Lopez-Mendez T; Rodriguez F; Paez-Espinosa V; Li C; Vallverdú NF; Edwards M; Moral A; Pérez JI; Escolà-Gil JC; Pedraz JL; Gallego I; Corcoy R; Céspedes MV; Puras G; Mato E
Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002329
[TBL] [Abstract] [Full Text] [Related]
6. NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of egfr signaling.
Qiao L; Dong C; Jia W; Ma B
Cell Signal; 2023 Dec; 112():110922. PubMed ID: 37827343
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer.
Chen D; Li L; Wang M; Hu X; Jiang J; Li W; Yang L; Fan M; Shi Y; Lv F; Liu Y
Front Immunol; 2023; 14():1086479. PubMed ID: 37795095
[TBL] [Abstract] [Full Text] [Related]
8. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now.
Qi X; Shi Q; Xuhong J; Zhang Y; Jiang J
Breast Cancer Res; 2023 Oct; 25(1):113. PubMed ID: 37789330
[TBL] [Abstract] [Full Text] [Related]
9. Network Pharmacology-Based Identification of Key Pharmacological Mechanism of Shen-qi-di-huang Decoction Acting on Uremia.
Zhang X; Chen XF; Chen WJ; Ding H; Zhang BX
Altern Ther Health Med; 2024 Jan; 30(1):44-50. PubMed ID: 37773677
[TBL] [Abstract] [Full Text] [Related]
10. Cardiorespiratory fitness and BMI measured in youth and 5-year mortality after site-specific cancer diagnoses in men-A population-based cohort study with register linkage.
Onerup A; Mehlig K; Ekblom-Bak E; Lissner L; Börjesson M; Åberg M
Cancer Med; 2023 Oct; 12(19):20000-20014. PubMed ID: 37732468
[TBL] [Abstract] [Full Text] [Related]
11. Lazertinib versus Gefitinib as First-Line treatment for egfr-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.
Lee KH; Cho BC; Ahn MJ; Lee YG; Lee Y; Lee JS; Kim JH; Min YJ; Lee GW; Lee SS; Lee KH; Ko YH; Shim BY; Kim SW; Shin SW; Choi JH; Kim DW; Cho EK; Park KU; Kim JS; Chun SH; Wang J; Choi S; Kang JH
Cancer Res Treat; 2024 Jan; 56(1):48-60. PubMed ID: 37402411
[TBL] [Abstract] [Full Text] [Related]
12. P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer.
Chen H; Si Y; Wen J; Hu C; Xia E; Wang Y; Wang O
Neoplasia; 2023 Sep; 43():100913. PubMed ID: 37348428
[TBL] [Abstract] [Full Text] [Related]
13. [Special tumor entities in the head and neck region: nasopharyngeal, salivary gland, and thyroid cancer].
Zech HB; Betz CS
HNO; 2023 Jul; 71(7):453-461. PubMed ID: 37294335
[TBL] [Abstract] [Full Text] [Related]
14. Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients.
Horesh A; Pollack R; Nechushtan H; Dresner-Pollak R; Neuman T
Pathol Oncol Res; 2023; 29():1610951. PubMed ID: 37139142
[No Abstract] [Full Text] [Related]
15. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the egfr signaling pathway.
Xiao Z; Li M; Zhang X; Rong X; Xu H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
[TBL] [Abstract] [Full Text] [Related]
16. Significance of miRNAs on the thyroid cancer progression and resistance to treatment with special attention to the role of cross-talk between signaling pathways.
Doghish AS; El-Mahdy HA; Ismail A; Hegazy M; Mokhtar MM; Elkhawaga SY; Elkady MA; Yehia AM; Elsakka EGE
Pathol Res Pract; 2023 Mar; 243():154371. PubMed ID: 36791561
[TBL] [Abstract] [Full Text] [Related]
17. Efficacy of Immunotherapy in Second-Line treatment of
Knetki-Wróblewska M; Tabor S; Płużański A; Lewandowska Z; Tysarowski A; Pawlik H; Kowalski DM; Krzakowski M
Curr Oncol; 2022 Dec; 30(1):462-475. PubMed ID: 36661686
[TBL] [Abstract] [Full Text] [Related]
18. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Wu J; Jiang Z; Liu Z; Yang B; Yang H; Tang J; Wang K; Liu Y; Wang H; Fu P; Zhang S; Liu Q; Wang S; Huang J; Wang C; Wang S; Wang Y; Zhen L; Zhu X; Wu F; Lin X; Zou J
BMC Med; 2022 Dec; 20(1):498. PubMed ID: 36575513
[TBL] [Abstract] [Full Text] [Related]
19. The complementary role of lymphovascular invasion and perineural invasion in the TNM staging process of rectal cancer.
Chen T; Wang M; Cheng X; Wang Y; Jiang Y; Fang X; Xiao H
Medicine (Baltimore); 2022 Sep; 101(39):e30687. PubMed ID: 36181060
[TBL] [Abstract] [Full Text] [Related]
20. Effects of high-activity radioactive iodine treatment on renal function in patients with differentiated thyroid carcinoma - retrospective study.
Yin L; Li W; Lv X; Lin Y; Jia Q; Tan J; Li X; Sun D; Wang Y; Meng Z
Endokrynol Pol; 2022; 73(3):619-626. PubMed ID: 36059177
[TBL] [Abstract] [Full Text] [Related]
[Next]